Davenport & Co’s Forte Biosciences FBRX Stock Holding History

Davenport & Co’s Portfolio FBRX Stock Details FBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-1,264	Closed	-$1.06M	–	1031
2021 Q2	$1.06M	Hold	1,264	–	–	0.01%	463
2021 Q1	$1.08M	Buy	1,264 +480	+61%	+$393K	0.01%	381
2020 Q4	$714K	Sell	784 -288	-27%	-$271K	0.01%	437
2020 Q3	$1.3M	Buy	+1,072	New	+$711K	0.01%	300

Other funds holding FBRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

OQS

Occudo Quantitative Strategies Fort Lauderdale, Florida $1.84B AUM 22.15% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

PPA

Parametric Portfolio Associates Seattle, Washington $190B AUM 18.52% 1-Year Est. Return

Davenport & Co's FBRX Position: Q3 2021 in Review

Davenport & Co sold out of Forte Biosciences (FBRX) in Q3 2021, closing a stake of 1,264 shares — an estimated $1.06M sold.

Davenport & Co first reported a position in FBRX in Q3 2020 and held it in 4 quarters. The position peaked at $1.3M in Q3 2020. 57 funds tracked by Wall St. Rank hold FBRX as of Q3 2021.

Davenport & Co reported no remaining Forte Biosciences position as of Q3 2021 after selling out during the quarter.
Davenport & Co sold 1,264 Forte Biosciences shares in Q3 2021, an estimated $1.06M.
Davenport & Co first reported a position in Forte Biosciences in Q3 2020 and held it in 4 quarters.
Davenport & Co's Forte Biosciences position peaked at $1.3M in Q3 2020.
57 funds tracked by Wall St. Rank held Forte Biosciences as of Q3 2021.

Based on Davenport & Co's 13F filing for Q3 2021, filed 14 Oct 2021.